Robert Garcia

Well, I think there are many analogies that are all kind of similar for something like this. And maybe pothole repair is an easy example to grasp. If you decide I want to cut the city budget, the expenses, you could say we're not going to fix any potholes for the next couple of years. And right away, you don't notice anything different.

But then over time, the risk of something bad happening goes up incrementally over time, and eventually someone's going to hit a pothole and something bad is going to happen. And so, I mean, we have industries in America and globally that supply America that produce pretty good products.

But then over time, the risk of something bad happening goes up incrementally over time, and eventually someone's going to hit a pothole and something bad is going to happen. And so, I mean, we have industries in America and globally that supply America that produce pretty good products.

But then over time, the risk of something bad happening goes up incrementally over time, and eventually someone's going to hit a pothole and something bad is going to happen. And so, I mean, we have industries in America and globally that supply America that produce pretty good products.

And so you wouldn't see something right away for the average person, but there will be harm done by products that are deficient that didn't get inspected on time. or safety reports that go out. One place that was cut substantially was the communications part of government. Someone's got to actually notify people when there's a safety problem.

And so you wouldn't see something right away for the average person, but there will be harm done by products that are deficient that didn't get inspected on time. or safety reports that go out. One place that was cut substantially was the communications part of government. Someone's got to actually notify people when there's a safety problem.

And so you wouldn't see something right away for the average person, but there will be harm done by products that are deficient that didn't get inspected on time. or safety reports that go out. One place that was cut substantially was the communications part of government. Someone's got to actually notify people when there's a safety problem.

The company has a role, but I don't think we want the companies taking full accountability for that. That's problems there is part of what led to the FDA being in place in the first place. But a place, just to mention one group I'm particularly worried about where who could see really big losses from expectations would be people with rare disease.

The company has a role, but I don't think we want the companies taking full accountability for that. That's problems there is part of what led to the FDA being in place in the first place. But a place, just to mention one group I'm particularly worried about where who could see really big losses from expectations would be people with rare disease.

The company has a role, but I don't think we want the companies taking full accountability for that. That's problems there is part of what led to the FDA being in place in the first place. But a place, just to mention one group I'm particularly worried about where who could see really big losses from expectations would be people with rare disease.

You're very aware, Vin, that we're on the threshold of treatments and cures for hundreds of thousands of diseases that were previously completely untreatable because of gene editing and other ways to affect the human genome. This is not possible until just now. But it's very complicated and it's a risky development process that needs a lot of interaction with the FDA.

You're very aware, Vin, that we're on the threshold of treatments and cures for hundreds of thousands of diseases that were previously completely untreatable because of gene editing and other ways to affect the human genome. This is not possible until just now. But it's very complicated and it's a risky development process that needs a lot of interaction with the FDA.

You're very aware, Vin, that we're on the threshold of treatments and cures for hundreds of thousands of diseases that were previously completely untreatable because of gene editing and other ways to affect the human genome. This is not possible until just now. But it's very complicated and it's a risky development process that needs a lot of interaction with the FDA.

And we're already seeing, for example, investors backing off because of the uncertainty as to whether there's enough staff left at FDA to work with the industry to develop these treatments. So I mean, this is not a matter like many of the diseases you and I deal with. I'm a cardiologist. We have a lot of treatments already. We're talking about people with no other treatment.

And we're already seeing, for example, investors backing off because of the uncertainty as to whether there's enough staff left at FDA to work with the industry to develop these treatments. So I mean, this is not a matter like many of the diseases you and I deal with. I'm a cardiologist. We have a lot of treatments already. We're talking about people with no other treatment.

And we're already seeing, for example, investors backing off because of the uncertainty as to whether there's enough staff left at FDA to work with the industry to develop these treatments. So I mean, this is not a matter like many of the diseases you and I deal with. I'm a cardiologist. We have a lot of treatments already. We're talking about people with no other treatment.

It's just one extreme example.

It's just one extreme example.

It's just one extreme example.

I think you're probably a better judge of that than I am. But my perception is it's just hard to connect the dots here for the average person. It's got a lot of other things to worry about in life. And this is not the kind of thing, at least not right now, where, you know, like your garbage is not picked up. You're going to know that right away.